Neurogene Inc. Reports Q3 2025 Financial Results
Neurogene Inc. reported a Q3 2025 net loss of $20.95 million, with operating expenses of $23.8 million. Cash decreased to $71 million, while short-term investments rose to $194.4 million. Despite losses, management is optimistic, expecting cash and investments to support operations for another year. The company plans to advance clinical programs and explore strategic partnerships to enhance financial stability.
Neurogene Inc. ( (NGNE) ) has released its Q3 earnings. Here is a breakdown of the information Neurogene Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Neurogene Inc. is a clinical-stage biotechnology company focused on developing gene therapies for neurological diseases, utilizing its proprietary EXACT transgene regulation technology. The company recently released its earnings report for the quarter ending September 30, 2025, highlighting key financial metrics and strategic developments. Neurogene reported a net loss of $20.95 million for the quarter, with total operating expenses amounting to $23.8 million. The company’s cash and cash equivalents decreased to $71 million, down from $136.6 million at the end of 2024, while short-term investments increased to $194.4 million. Despite the losses, Neurogene’s management remains optimistic about its financial position, with cash and investments expected to support operations for at least another year. Looking ahead, Neurogene plans to continue advancing its clinical programs and exploring strategic partnerships to enhance its financial stability and support its mission of transforming neurological disease treatment.
